Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity.

Hsu YC, Chen HY, Yuan S, Yu SL, Lin CH, Wu G, Yang PC, Li KC.

BMC Med. 2013 Apr 16;11:106. doi: 10.1186/1741-7015-11-106.

2.

A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer.

Hsu YC, Yuan S, Chen HY, Yu SL, Liu CH, Hsu PY, Wu G, Lin CH, Chang GC, Li KC, Yang PC.

Clin Cancer Res. 2009 Dec 1;15(23):7309-15. doi: 10.1158/1078-0432.CCR-09-1572. Epub 2009 Nov 17.

3.

Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.

Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J, Vallyathan V, Castranova V, Guo NL.

PLoS One. 2010 Aug 17;5(8):e12222. doi: 10.1371/journal.pone.0012222.

4.
5.

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.

Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98.

6.

Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma.

Chao YC, Pan SH, Yang SC, Yu SL, Che TF, Lin CW, Tsai MS, Chang GC, Wu CH, Wu YY, Lee YC, Hong TM, Yang PC.

Am J Respir Crit Care Med. 2009 Jan 15;179(2):123-33. doi: 10.1164/rccm.200803-456OC. Epub 2008 Sep 11.

PMID:
18787218
7.

Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.

Fiebig HH, Schüler J, Bausch N, Hofmann M, Metz T, Korrat A.

Cancer Genomics Proteomics. 2007 May-Jun;4(3):197-209.

8.

MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.

Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, Shen CY.

Breast Cancer Res Treat. 2012 Aug;134(3):1081-93. doi: 10.1007/s10549-012-2034-4. Epub 2012 Apr 4.

PMID:
22476851
9.

Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.

Baty F, Facompré M, Kaiser S, Schumacher M, Pless M, Bubendorf L, Savic S, Marrer E, Budach W, Buess M, Kehren J, Tamm M, Brutsche MH.

Am J Respir Crit Care Med. 2010 Jan 15;181(2):181-8. doi: 10.1164/rccm.200812-1807OC. Epub 2009 Oct 15.

PMID:
19833826
10.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd..

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
11.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer..

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
12.

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D.

J Clin Oncol. 2004 May 1;22(9):1564-71. Epub 2004 Mar 29.

PMID:
15051756
13.

Chemosensitivity prediction by transcriptional profiling.

Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10787-92.

14.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.

15.

Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.

Kadra G, Finetti P, Toiron Y, Viens P, Birnbaum D, Borg JP, Bertucci F, Gonçalves A.

Breast Cancer Res Treat. 2012 Apr;132(3):1035-47. doi: 10.1007/s10549-011-1687-8. Epub 2011 Jul 27. Erratum in: Breast Cancer Res Treat. 2012 Jul;134(1):449-51.

PMID:
21792624
16.

Prediction of breast cancer prognosis by gene expression profile of TP53 status.

Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N, Ishioka C.

Cancer Sci. 2008 Feb;99(2):324-32. doi: 10.1111/j.1349-7006.2007.00691.x.

17.

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.

Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E.

Cancer Res. 2007 Mar 1;67(5):2226-38.

18.

Molecular phenotyping of circulating tumour cells in patients with prostate cancer: prediction of distant metastases.

Giesing M, Driesel G, Molitor D, Suchy B.

BJU Int. 2012 Dec;110(11 Pt C):E1202-11. doi: 10.1111/j.1464-410X.2012.11534.x. Epub 2012 Oct 9.

19.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M.

J Natl Cancer Inst. 2005 May 4;97(9):643-55.

PMID:
15870435
20.

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.

Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, Chuang EY.

PLoS One. 2012;7(9):e45831. doi: 10.1371/journal.pone.0045831. Epub 2012 Sep 25.

Supplemental Content

Support Center